Argentina Continuous Glucose Monitoring Market - Strategic Insights and Forecasts (2026-2031)

The Argentina Continuous Glucose Monitoring market is forecast to grow at a CAGR of 15.7%, reaching USD 58.0 million in 2031 from USD 28.0 million in 2026.

The Argentine continuous glucose monitoring (CGM) market is currently undergoing a period of structural expansion as the rising prevalence of Type 1 and Type 2 diabetes is driving demand for advanced self-monitoring technologies. healthcare providers are responding to this shift by prioritizing CGM adoption in big cities where infrastructure and private insurance coverage facilitate access to premium devices. This transition is becoming critical as the National Administration of Drugs, Food and Medical Technology (ANMAT) is currently intensifying its post-market surveillance to ensure the safety and efficacy of imported medical electronics. Regulatory influence is further increasing through the 2026 "Alliance for Primary Health Care" initiative, which is currently focusing on reducing service fragmentation and closing access gaps in chronic care. Consequently, the industry is reaching an outcome where clinical adoption in hospitals is expanding alongside a dominant home-care segment.

MARKET DYNAMICS

Drivers

• Increasing Diabetes Awareness: National advocacy efforts are currently boosting recognition of early diagnosis and proper management, particularly in large economies like Argentina.

• Sensor Miniaturization: Technological breakthroughs in hardware design are currently increasing user engagement and comfort, potentially driving higher market demand.

• Shift Toward Preventive Healthcare: A strong push for proactive management is currently encouraging patients to adopt CGM to avoid emergency hospital visits.

• Smartphone Compatibility: The widespread availability of NFC and Bluetooth-enabled smartphones is currently facilitating the seamless integration of CGM data into daily life.

Restraints and Opportunities

• High Out-of-Pocket Costs: Limited reimbursement and high device costs are continuing to constrain overall market penetration in price-sensitive segments.

• Regulatory Complexity: New ANMAT deadlines and notification criteria for medical devices are currently increasing the administrative burden for international importers.

• Integrated Insulin Pumps (Opportunity): The rapid growth of integrated-CGM insulin pump systems is providing a significant opening for high-end market expansion through 2033.

• Primary Health Care Transformation (Opportunity): Argentina's 2026 entry into the Alliance for Primary Health Care is creating a path for more coordinated, technology-supported chronic disease management.

SUPPLY CHAIN ANALYSIS

The CGM supply chain in Argentina is currently transitioning toward a digital-first model where data management platforms act as the primary interface between manufacturers and users. Importers are increasing their focus on regulatory compliance to meet updated ANMAT post-market surveillance standards. This evolution is becoming critical as established global players are currently leveraging local distributor networks to address the uneven reimbursement landscape.

GOVERNMENT REGULATIONS

KEY DEVELOPMENTS

• Alliance for Primary Health Care Accession (March 2026): Argentina joined the regional PAHO alliance to accelerate health system transformation and prioritize primary care.

• Abbott-Medtronic Global Partnership (August 2024): The firms announced a critical step to integrate Abbott's sensor technology with Medtronic's automated insulin delivery systems.

• ANMAT Surveillance Update (March 2024): The Head of the IVD Medical Device Office provided updated guidance on surveillance concepts and notification criteria.

MARKET SEGMENTATION

By Application

Diabetes patients currently account for the vast majority of the market as CGM becomes the standard for Type 1 management and high-risk Type 2 cases. Critical patients in hospital settings are witnessing a steady increase in adoption as inpatient-glycemic-control protocols incorporate real-time sensor streams to reduce acute complications. This transition is resulting in a market where specialized sensors are increasingly tailored for both long-term chronic wear and short-term intensive care.

By End User

Home care is currently the leading end-user segment because patients are prioritizing the convenience of monitoring their condition from home. Hospitals and specialty clinics are expanding their use of CGM as remote patient-monitoring reimbursements motivate clinicians to use data for proactive rather than crisis care. Consequently, diagnostic centers and clinics are reaching an outcome where they serve as the primary hubs for device initiation and data-driven tele-consultations.

COMPETITIVE LANDSCAPE

• Dexcom, Inc.

• Abbott Laboratories

• Medtronic plc

• Roche Diabetes Care, Inc.

• Senseonics Holdings, Inc.

• Ascensia Diabetes Care

• Insulet Corporation

• Tandem Diabetes Care, Inc.

• ECHO Therapeutics, Inc.

• Terumo Corporation

Company Profiles

• Abbott Laboratories: Strategically distinct for its high market share in Latin America, the company is successfully leveraging its FreeStyle Libre brand to lead the shift toward affordable, sensor-based monitoring.

• Dexcom, Inc.: Notable for its technological innovation, the company is currently driving the adoption of real-time CGM through advanced mobile application integration and strategic digital health investments.

• Medtronic plc: Distinguished by its focus on integrated care, the company is successfully maintaining a solid presence through its MiniMed insulin pump systems and Guardian sensors in advanced private healthcare settings.

ANALYST VIEW

The Argentine CGM market is entering a "Precision Integration" phase. Success for participants now depends on providing seamless, data-rich ecosystems that successfully connect home-care patients with hospital-grade analytics through 2031.

Argentina Continuous Glucose Monitoring Market Scope: